| |
Non-survivor, N = 53
|
Survivor, N = 67
|
p overall
|
|---|
|
Age 65
|
0.248
|
|
< 65
|
37 (69.8%)
|
54 (80.6%)
|
|
> 65
|
16 (30.2%)
|
13 (19.4%)
|
|
Sex
|
1.000
|
|
F
|
10 (18.9%)
|
12 (17.9%)
|
|
M
|
43 (81.1%)
|
55 (82.1%)
|
|
AFP (ng/ml)
|
36.1 [5.40; 234]
|
6.20 [3.50; 26.5]
|
< 0.001
|
|
Waiting_time (days)
|
236 [77.0; 370]
|
198 [64.5; 316]
|
0.319
|
|
D (mm)
|
36.8 (20.1)
|
30.3 (21.1)
|
0.091
|
|
MELD
|
0.703
|
|
MELD ≤ 15
|
29 (69.0%)
|
42 (76.4%)
|
|
MELD = 15–30
|
9 (21.4%)
|
8 (14.5%)
|
|
MELD > 30
|
4 (9.52%)
|
5 (9.09%)
|
|
preTreat
|
0.319
|
|
No pre-treatment
|
23 (43.4%)
|
22 (32.8%)
|
|
Pre-treatment
|
30 (56.6%)
|
45 (67.2%)
|
|
N
|
0.109
|
|
N = 1
|
18 (48.6%)
|
41 (65.1%)
|
|
N = 1–3
|
12 (32.4%)
|
18 (28.6%)
|
|
N > 3
|
7 (18.9%)
|
4 (6.35%)
|
|
Grade
|
0.559
|
|
1
|
8 (32.0%)
|
15 (44.1%)
|
|
2
|
15 (60.0%)
|
18 (52.9%)
|
|
3
|
2 (8.00%)
|
1 (2.94%)
|
|
Asan
|
< 0.001
|
|
Exceeding
|
25 (47.2%)
|
10 (14.9%)
|
|
Fulfilling
|
28 (52.8%)
|
57 (85.1%)
|
|
AFP score
|
0.002
|
|
> 2
|
18 (40.9%)
|
8 (13.1%)
|
|
≤ 2
|
26 (59.1%)
|
53 (86.9%)
|
|
MC
|
0.001
|
|
Exceeding
|
30 (56.6%)
|
16 (23.9%)
|
|
Fulfilling
|
23 (43.4%)
|
51 (76.1%)
|
|
UTS
|
< 0.001
|
|
Exceeding
|
26 (49.1%)
|
8 (11.9%)
|
|
Fulfilling
|
27 (50.9%)
|
59 (88.1%)
|
- Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
- AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria
